LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

LLY

993.35

+1.19%↑

JNJ

206.6

+3.36%↑

ABBV

225.03

+1%↑

UNH

327.77

+1.31%↑

AZN

91.43

+2.09%↑

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Cerrado

SectorSanidad

22.74 1.34

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

22.18

Máximo

22.84

Métricas clave
By Trading Economics
Ingresos	675K 53M
Ventas	1.8M 148M
P/B Media del Sector	13.544 77.671
Margen de beneficios	35.57
Empleados	181
EBITDA	1.7M 80M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+50.78% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	223M 2.8B
Apertura anterior	21.4
Cierre anterior	22.74

Noticias sobre sentimiento de mercado

By Acuity

56%

44%

329 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

N/A / 24.28 Soporte y Resistencia

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

10 dic 2025, 22:02 UTC

Ganancias

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 dic 2025, 21:46 UTC

Ganancias

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 dic 2025, 23:52 UTC

Adquisiciones, fusiones, absorciones

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 dic 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 dic 2025, 23:36 UTC

Charlas de Mercado

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 dic 2025, 23:20 UTC

Ganancias

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 dic 2025, 23:15 UTC

Ganancias

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 dic 2025, 22:59 UTC

Charlas de Mercado

Ganancias

Adquisiciones, fusiones, absorciones

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 dic 2025, 22:45 UTC

Charlas de Mercado

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 dic 2025, 22:40 UTC

Ganancias

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dic 2025, 22:06 UTC

Adquisiciones, fusiones, absorciones

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dic 2025, 22:06 UTC

Ganancias

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dic 2025, 22:02 UTC

Ganancias

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dic 2025, 22:00 UTC

Ganancias

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 dic 2025, 21:53 UTC

Ganancias

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dic 2025, 21:50 UTC

Adquisiciones, fusiones, absorciones

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 dic 2025, 21:50 UTC

Charlas de Mercado

Ganancias

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

10 dic 2025, 21:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

10 dic 2025, 21:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

10 dic 2025, 21:45 UTC

Adquisiciones, fusiones, absorciones

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dic 2025, 21:33 UTC

Ganancias

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 dic 2025, 21:32 UTC

Ganancias

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dic 2025, 21:28 UTC

Adquisiciones, fusiones, absorciones

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 dic 2025, 21:25 UTC

Ganancias

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dic 2025, 21:18 UTC

Adquisiciones, fusiones, absorciones

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 dic 2025, 21:16 UTC

Ganancias

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 dic 2025, 21:15 UTC

Adquisiciones, fusiones, absorciones

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 dic 2025, 21:15 UTC

Ganancias

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 dic 2025, 21:14 UTC

Ganancias

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 dic 2025, 21:14 UTC

Ganancias

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

50.78% repunte

Estimación a 12 Meses

Media 34 USD 50.78%

Máximo 35 USD

Mínimo 33 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

329 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.